Lung Diseases, Interstitial, Lung Disease With Systemic Sclerosis
Conditions
Keywords
Progressive fibrosing interstitial lung disease, Systemic Sclerosis-Associated Interstitial Lung Disease
Brief summary
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders, which encompass a wide range of conditions. In some patients with fibrosing ILDs, a progressive phenotype similar to that observed in idiopathic pulmonary fibrosis (IPF) may develop during the course of the disease (PF-ILD), including patients with systemic sclerosis (SSc)-related ILD. The aim of the study is to estimate the incidence and prevalence and to describe the characteristics of patients diagnosed with non-IPF PF-ILD and SSc-ILD, to describe the natural course of disease, and to explore the correlation between mortality and Forced Vital Capacity (FVC) of the patients with non-IPF PF-ILD. This study will be based on two data sources: the French national medico administrative database (SNDS) and the ILD cohort from the National French center for rare pulmonary diseases in Lyon, France.
Interventions
OTHERepidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD
epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients hospitalized for PF-ILD and SSc-ILD in France between 01/01/2010 and 31/12/2017 * Men or women aged ≥ 18 years old at diagnosis
Exclusion criteria
* Patients treated by anti-fibrotic * Patients diagnosed with IPF
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of PF-ILD and SSc-ILD patients | Between 2010 and 2017 | The study will describe for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) patients in France.: * the epidemiology (incidence and prevalence), * the characteristics of patients, * the healthcare resource use and associated costs |
| healthcare resource use of PF-ILD and SSc-ILD patients | Between 2010 and 2017 | The study will describe for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) patients in France.: * the epidemiology (incidence and prevalence), * the characteristics of patients, * the healthcare resource use and associated costs |
| associated costs of PF-ILD and SSc-ILD patients | Between 2010 and 2017 | The study will describe for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) patients in France.: * the epidemiology (incidence and prevalence), * the characteristics of patients, * the healthcare resource use and associated costs |
| Incidence of PF-ILD and SSc-ILD patients | Between 2010 and 2017 | The study will describe for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) patients in France.: * the epidemiology (incidence and prevalence), * the characteristics of patients, * the healthcare resource use and associated costs |
| characteristics of PF-ILD and SSc-ILD patients | Between 2010 and 2017 | The study will describe for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) patients in France.: * the epidemiology (incidence and prevalence), * the characteristics of patients, * the healthcare resource use and associated costs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Forced Vital Capacity for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) in France. | Between 2010 and 2017 | correlation between mortality and FVC for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) in France. |
| mortality for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) in France. | Between 2010 and 2017 | correlation between mortality and FVC for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) in France. |
Countries
France
Contacts
Primary ContactVincent Cottin, Pr
Outcome results
None listed